MMRGlobal Discusses M&A Strategy in Conference Call With Shareholders

LOS ANGELES, CA--(Marketwire - Dec 5, 2011) - MMRGlobal, Inc. (OTCBB: MMRF) ("MMR"), in a conference call with shareholders last week, discussed its strategy to identify transactions with large privately held companies in healthcare, health IT and revenue cycle management that have expressed interest in becoming publicly traded. MMR previously reported the existence of a non-binding term sheet with a company in which negotiations are taking place. MMR is also pursuing other existing opportunities at the same time to ensure that any transaction will be the best one available for its shareholders. Valuations for publicly traded companies in the healthcare space are at an all time high, ranging from multiples of more than five times revenue to more than 20 times EBITDA. Growth in valuations is attributed to guidelines, requirements and regulations of the Health Information Technology for Economic and Clinical Health Act (HITECH) creating significant business opportunities for companies in healthcare IT. Completion of a transaction could result in significantly increased valuations to shareholders of MMR and the opportunity for the Company to secure listing on a national exchange. (Interested investors may listen to the MMRGlobal conference call in its entirety currently available at http://phx.corporate-ir.net/phoenix.zhtml?p=irol-eventDetails&c=178404&eventID=4250082)

"This strategy is similar to one I used in the past when I was CEO of a prepaid calling card company. I founded that company with $5,000 and through a series of mergers and acquisitions with larger revenue companies, it grew into a billion dollar NASDAQ market cap company," said Robert H. Lorsch, Chairman and CEO of MMRGlobal. "A lot of larger private companies in health IT and revenue cycle management want to be able to take advantage of the value in their equity by being in the public market, however, they cannot because of the difficulty to bring a public offering in the current financial climate. Existing MMR shareholders would get the benefit of significant revenue multiples while the Company could get the benefit of qualifying for listing on a national market exchange."

MMR provides Personal Health Records through its MyMedicalRecords product line for patients and Electronic Document Imaging Systems through its MMRPro system for healthcare professionals. Information on the Company's products and services can be found at www.mmrtheater.com and www.mmrglobal.com. The Company also holds an intellectual property portfolio consisting of patents for Health Information Technology applications which are being successfully licensed worldwide. Additionally, MMR holds a portfolio of biotech assets acquired through its reverse merger in 2009 with Favrille, Inc., which spent more than 100 million dollars in development of intellectual property that includes biotech patents and patient samples which the Company is working to license to biotech companies, universities and others. The Company has already demonstrated its ability to license these assets to Big Pharma.

Earlier this year, MMRGlobal retained The MichaelBass Group, a leader in the healthcare information technology field, to assist the Company in valuing potential merger candidates. Physicians and hospitals are also helping to drive public valuations by rapidly digitizing paper-based records and purchasing EMR systems to qualify for meaningful use incentives prior to the 2014 deadlines imposed by HITECH that is part of the American Recovery and Reinvestment Act of 2009 (aka Stimulus bill).

About MMRGlobal, Inc.

MMRGlobal, Inc., through its wholly-owned operating subsidiary, MyMedicalRecords, Inc. ("MMR"), provides secure and easy-to-use online Personal Health Records ("PHRs") and electronic safe deposit box storage solutions, serving consumers, healthcare professionals, employers, insurance companies, financial institutions, and professional organizations and affinity groups. The MyMedicalRecords PHR enables individuals and families to access their medical records and other important documents, such as birth certificates, passports, insurance policies and wills, anytime from anywhere using the Internet. MyMedicalRecords is built on proprietary, patented technologies to allow documents, images and voicemail messages to be transmitted and stored in the system using a variety of methods, including fax, phone, or file upload without relying on any specific electronic medical record platform to populate a user's account. The Company's professional offering, MMRPro, is designed to give physicians' offices an easy and cost-effective solution to digitizing paper-based medical records and sharing them with patients in real time through an integrated patient portal. MMR is an Independent Software Vendor Partner with Kodak to deliver an integrated turnkey EMR solution for healthcare professionals. Through its merger with Favrille, Inc. in January 2009, the Company acquired intellectual property biotech assets that include anti-CD20 antibodies and data and samples from its FavId™/Specifid™ vaccine clinical trials for the treatment of B-Cell Non-Hodgkin's lymphoma. To learn more about MMRGlobal, Inc. and its products, visit www.mmrglobal.com.

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature, including statements related to the Company's M&A transaction strategy and plans, healthcare and health IT valuations, listing on a national exchange and others; future performance, and management's expectations, beliefs, intentions, estimates or projections, constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. Some can be identified by the use of words (and their derivations) such as "need," "possibility," "offer," "development," "if," "negotiate," "when," "begun," "believe," "achieve," "will," "estimate," "expect," "maintain," "plan," and "continue," or the negative of these words. Factors that could cause or contribute to such differences include, but are not limited to, the risk the Company's products are not adopted or viewed favorably by the healthcare community and consumer retail market; the risk the Company and JERCS, Inc. as parties to the non-binding term sheet will reach a definitive agreement with respect to any contemplated transactions, and even if consummated, the Company cannot guaranty that the transactions will be consummated on terms favorable to the Company and/or its stockholders; risks related to the current uncertainty and instability in financial and lending markets, including global economic uncertainties; product integration in physician practices and hospitals; timing and volume of sales and installations; length of sales cycles and the installation process; market acceptance of new product introductions; ability to establish and maintain strategic relationships; ability to identify and integrate acquisitions; relationships with licensees; competitive product offerings and promotions; changes in government laws and regulations and future changes in tax legislation and initiatives in the healthcare industry; undetected errors in our products; possibility of interruption at our data centers; risks related to third party vendors; risks related to obtaining and integrating third-party licensed technology; acceptance of the Company's marketing and promotional campaigns; risks related to a security breach by third parties; maintaining, developing, defending, marketing and licensing our intellectual property rights including those pertaining to our biotechnology assets; the risk and uncertainties inherent in litigation; risks associated with recruitment and retention of key personnel; uncertainties associated with doing business internationally across borders and territories; and additional risks discussed in the Company's filings with the Securities and Exchange Commission. Additionally, we are a developing early-stage company and many variables can affect revenues and/or projections, including factors out of our control. The Company is providing this information as of the date of this release and, except as required by law, does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.